Last reviewed · How we verify
Yishen Qutong Simulant Granules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Yishen Qutong Simulant Granules (Yishen Qutong Simulant Granules) — Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Yishen Qutong Simulant Granules TARGET | Yishen Qutong Simulant Granules | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Yishen Qutong Simulant Granules CI watch — RSS
- Yishen Qutong Simulant Granules CI watch — Atom
- Yishen Qutong Simulant Granules CI watch — JSON
- Yishen Qutong Simulant Granules alone — RSS
Cite this brief
Drug Landscape (2026). Yishen Qutong Simulant Granules — Competitive Intelligence Brief. https://druglandscape.com/ci/yishen-qutong-simulant-granules. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab